Stockscreener 앱 받기
1.79
7.83%
0.13
Theratechnologies Inc 주식(THTX)의 최신 뉴스
Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV® - TipRanks
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment - The Manila Times
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® ... - Russellville Courier
Theratechnologies Seeks FDA Approval for EGRIFTA SV® Manufacturing Changes Amid Supply Concerns - StockTitan
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Closing Bell: Theratechnologies Up On Wednesday (TH) - Barchart
Theratechnologies (TSE:TH) Stock Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
Theratechnologies Secures Canadian Rights for Ionis RNA Medicines - TipRanks
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Decreases By 44.0% - MarketBeat
Theratechnologies Inc. Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - Marketscreener.com
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - GlobeNewswire
Theratechnologies Awaits FDA Decision on New EGRIFTA Formulation, Sets March 2025 PDUFA Date - StockTitan
Theratechnologies Shows Promise in Ovarian Cancer Trial - TipRanks
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer - GlobeNewswire
Theratechnologies' Cancer Drug Shows Promise: Tumor Shrinkage in Phase 1b Trial - StockTitan
Theratechnologies expands rare disease portfolio with Ionis partnership - MSN
Theratechnologies enters exclusive licensing agreement with Ionis - Yahoo Finance
Theratechnologies expands rare disease portfolio with Ionis partnership | 2024-12-04 | Investing News - Stockhouse Publishing
Theratechnologies Expands Portfolio with Ionis Deal - TipRanks
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen - The Bakersfield Californian
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada - GlobeNewswire
Theratechnologies Secures Exclusive Rights to Two Breakthrough Rare Disease Drugs in $22.75M Deal - StockTitan
EGRIFTA SV production restarts after FDA inspection - Investing.com India
Theratechnologies resumes production of EGRIFTA SV - MSN
EGRIFTA SV production restarts after FDA inspection By Investing.com - Investing.com Nigeria
Theratechnologies resumes production of Egrifta SV - Nasdaq
Theratechnologies Announces Resumed Production of EGRIFTA SV® - GlobeNewswire
Theratechnologies Inc. Announces Resume Production of EGRIFTA SV - Marketscreener.com
Theratechnologies secures up to $75M in new credit facilities - Yahoo Finance
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec - GlobeNewswire
Theratechnologies Secures $75M Credit Facility with Improved Terms, Freeing Up $19M Cash - StockTitan
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and ... - Russellville Courier
Theratechnologies resubmits BLA for new tesamorelin formulation - MSN
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review - Marketscreener.com
Theratechnologies Resubmits Tesamorelin Application to FDA - TipRanks
Theratechnologies Resubmits FDA Application for Improved HIV Treatment Formulation | THTX Stock News - StockTitan
Theratechnologies Inc. (TSE:TH) Has Found A Path To Profitability - Yahoo Finance
Analyzing Inozyme Pharma (NASDAQ:INZY) and Theratechnologies (NASDAQ:THTX) - Defense World
Theratechnologies Inc. (NASDAQ:THTX) Sees Large Growth in Short Interest - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 26.8% in October - Defense World
Theratechnologies (TSE:TH) Share Price Passes Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Lipodystrophy Market: Company Profiles, Segment Size, - openPR
Net Present Value Model: Theratechnologies Inc’s Sudocetaxel Zendusortide - GlobalData
Theratechnologies (TSE:TH) Stock Passes Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Rises By 226.0% - MarketBeat
Closing Bell: Theratechnologies Down On Monday (TH) - Barchart
THTX upgraded at Research Capital - Cantech Letter
Theratechnologies (TSE:TH) Stock Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV - The Manila Times
Theratechnologies reports use of HIV drug in severe cases - Investing.com
Theratechnologies reports use of HIV drug in severe cases By Investing.com - Investing.com South Africa
2.88%
2.65%
자본화:
|
볼륨(24시간):